NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
BörsenkürzelNIVF
Name des UnternehmensNewGenIvf Group Ltd
IPO-datumFeb 15, 2022
CEOWing Fung (Siu)
Anzahl der mitarbeiter76
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 15
Addresse13/F, Ps Tower, Sukhumvit 21 Rd (Asoke)
StadtBANGKOK
BörseNASDAQ OMX - NASDAQ BASIC
LandThailand
Postleitzahl- -
Telefon
Websitehttps://newgenivf.com/
BörsenkürzelNIVF
IPO-datumFeb 15, 2022
CEOWing Fung (Siu)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten